You have 9 free searches left this month | for more free features.

selumetinib

Showing 1 - 25 of 59

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative Trial in Beijing, Shanghai (Selumetinib, Placebo)

Not yet recruiting
  • Neurofibromatosis Type 1
  • +2 more
  • Selumetinib
  • Placebo
  • Beijing, China
  • +2 more
Apr 11, 2023

Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1 (NF1)
  • Plexiform Neurofibromas (PN)
  • Selumetinib
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 31, 2023

Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

Active, not recruiting
  • Neurofibromatosis 1
  • Neurofibroma Plexiform
  • Selumetinib
  • Shanghai, China
  • +1 more
Jan 13, 2023

Uveal Melanoma Trial in New York, Houston (Selumetinib)

Active, not recruiting
  • Uveal Melanoma
  • Selumetinib
  • New York, New York
  • +2 more
Jun 28, 2022

Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib)

Active, not recruiting
  • Neurofibromatosis Type 1
  • Selumetinib
  • Rochester, Minnesota
  • +8 more
Nov 10, 2022

Stage IIIB NSCLC AJCC v7, Stage IV NSCLC AJCC v7 Trial in Portland (Laboratory Biomarker Analysis, Paclitaxel, Pharmacological

Completed
  • Stage IIIB Non-Small Cell Lung Cancer AJCC v7
  • Stage IV Non-Small Cell Lung Cancer AJCC v7
  • Laboratory Biomarker Analysis
  • +3 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Sep 14, 2022

Chronic Myeloid Leukemia, Myelofibroses Trial in Chicago (Azacitidine, Selumetinib)

Recruiting
  • Chronic Myeloid Leukemia
  • Myelofibroses
  • Chicago, Illinois
    The University of Chicago
May 16, 2022

NSCLC Trial in Boston, Durham (Osimertinib, Selumetinib)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Boston, Massachusetts
  • +3 more
Aug 1, 2022

Neurofibromatosis Type 1 Trial in Japan (Selumetinib)

Active, not recruiting
  • Neurofibromatosis Type 1
  • Selumetinib
  • Minato-ku, Japan
  • +3 more
Jun 9, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston

Recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • +3 more
  • Durvalumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 10, 2022

Advanced/Metastatic Solid Tumors Trial in Canada, United States (Selumetinib, Pembrolizumab)

Completed
  • Advanced/Metastatic Solid Tumors
  • Selumetinib
  • Pembrolizumab
  • Duarte, California
  • +5 more
Jul 8, 2022

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma Trial in Portland (procedure, drug,

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic Triple-Negative Breast Carcinoma
  • Biopsy
  • +6 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jul 29, 2022

Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 Trial in United States (Selumetinib, Sirolimus)

Active, not recruiting
  • Malignant Peripheral Nerve Sheath Tumors
  • Neurofibromatosis 1
  • Washington, District of Columbia
  • +4 more
Apr 1, 2022

Malignant Tumor of Breast, Malignant Tumors of Digestive Organs, Malignant Tumors of Female Genital Organs Trial in Houston

Recruiting
  • Malignant Neoplasm of Breast
  • +4 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 29, 2021

MPNST, NF1, Sarcoma Trial in United States (Selumetinib)

Not yet recruiting
  • MPNST
  • +2 more
  • Selumetinib
  • Birmingham, Alabama
  • +13 more
Jun 29, 2022

Neurofibromatosis Type 1, Plexiform Neurofibroma, Optic Nerve Glioma Trial in London (Selumetinib)

Recruiting
  • Neurofibromatosis Type 1
  • +2 more
  • Selumetinib
  • London, United Kingdom
  • +1 more
Nov 11, 2021

Neurofibromatosis 1, Plexiform Neurofibroma (PN) Trial in Worldwide (Selumetinib, Placebo)

Recruiting
  • Neurofibromatosis 1
  • Plexiform Neurofibroma (PN)
  • Selumetinib
  • Placebo
  • Gainesville, Florida
  • +40 more
Jan 16, 2023

Biliary Tract Carcinoma, Gallbladder Carcinoma Trial in Toronto (Selumetinib, Cisplatin, Gemcitabine)

Active, not recruiting
  • Biliary Tract Carcinoma
  • Gallbladder Carcinoma
  • Selumetinib
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Apr 14, 2021

Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric Trial in Denmark,

Recruiting
  • Acute Lymphoblastic Leukemia
  • +4 more
  • Copenhagen, Denmark
  • +16 more
Jan 26, 2022

NSCLC Trial in Canada (Selumetinib, Pemetrexed, Cisplatin)

Completed
  • Non-Small Cell Lung Cancer
  • Selumetinib
  • +3 more
  • Calgary, Alberta, Canada
  • +11 more
May 28, 2021

Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer Trial in San Francisco, Columbus

Completed
  • Adenocarcinoma of the Pancreas
  • +3 more
  • erlotinib hydrochloride
  • +2 more
  • San Francisco, California
  • +1 more
Jul 29, 2020

NF type1 With Inoperable Plexiform Neurofibromas Trial in New Orleans (Selumetinib)

Approved for marketing
  • NF type1 With Inoperable Plexiform Neurofibromas
  • Selumetinib
  • New Orleans, Louisiana
    Research Site
Apr 30, 2020

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV Trial in Worldwide (Selumetinib, Docetaxel, Placebo)

Active, not recruiting
  • Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
  • Selumetinib
  • +3 more
  • Aurora, Colorado
  • +196 more
Dec 22, 2022

Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma, Micropapillary Serous Carcinoma Trial in United States

Completed
  • Borderline Ovarian Serous Tumor
  • +5 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Los Angeles, California
  • +48 more
Dec 2, 2020

Non Small Cell Lung Cancer Trial in Canada (Paclitaxel, Carboplatin, Selumetinib)

Completed
  • Non Small Cell Lung Cancer
  • Vancouver, British Columbia, Canada
  • +3 more
Apr 6, 2020